文献速递临床试验与 GCP基础与转化研究

区域枸橼酸抗凝与全身肝素抗凝对危重急性肾损伤患者连续肾脏替代治疗滤器寿命和死亡率的影响:随机临床试验

Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

在德国26个中心进行的随机对照试验,纳入596例危重急性肾损伤患者,比较区域枸橼酸抗凝与全身肝素抗凝对滤器寿命和90天死亡率的影响。结果显示区域枸橼酸组中位滤器寿命显著延长(47 vs 26小时),但90天死亡率无显著差异;区域枸橼酸组出血并发症更少,新发感染更多。

要点

  • 区域枸橼酸抗凝较全身肝素显著延长滤器寿命(中位47 vs 26小时)。
  • 两组90天死亡率无显著差异(51.2% vs 53.6%)。
  • 区域枸橼酸组出血并发症更少,但新发感染更多。

核心结论

  • 在危重急性肾损伤接受连续肾脏替代治疗的患者中,区域枸橼酸抗凝相比全身肝素抗凝显著延长滤器寿命。
  • 该试验提前终止,检验效能不足以就抗凝策略对死亡率的影响得出结论。

研究设计与样本

  • 平行组、随机、多中心临床试验,在德国26个中心进行,2016年3月至2018年12月,最终随访至2020年1月21日。
  • 纳入596例危重急性肾损伤或具有肾脏替代治疗临床指征的患者,随机分配至区域枸橼酸抗凝组(n=300)或全身肝素抗凝组(n=296)。
  • 区域枸橼酸抗凝目标离子钙水平1.0-1.40 mg/dL;全身肝素抗凝目标活化部分凝血活酶时间45-60秒。
  • 共同主要结局为滤器寿命和90天死亡率。

主要发现

  • 区域枸橼酸组 vs 全身肝素组中位滤器寿命:47小时(IQR 19-70) vs 26小时(IQR 12-51),差异15小时(95%CI 11-20),P<.001。
  • 90天全因死亡率:区域枸橼酸组150/300 vs 肝素组156/296,Kaplan-Meier估计百分比51.2% vs 53.6%,未调整差异-2.4%(95%CI -10.5%至5.8%),未调整HR 0.91(95%CI 0.72-1.13),未调整P=.38;调整差异-6.1%(95%CI -12.6%至0.4%),主要调整HR 0.79(95%CI 0.63-1.004),主要调整P=.054。
  • 区域枸橼酸组出血并发症显著更少:15/300(5.1%) vs 49/296(16.9%),差异-11.8%(95%CI -16.8%至-6.8%),P<.001。
  • 区域枸橼酸组新发感染显著更多:204/300(68.0%) vs 164/296(55.4%),差异12.6%(95%CI 4.9%至20.3%),P=.002。
  • 38个预设次要终点中34个无显著差异。

临床怎么用

  • 对于危重急性肾损伤接受连续肾脏替代治疗的患者,区域枸橼酸抗凝可延长滤器寿命并减少出血并发症,但需警惕新发感染风险。
  • 区域枸橼酸抗凝目标离子钙1.0-1.40 mg/dL;全身肝素抗凝目标活化部分凝血活酶时间45-60秒。

局限性

  • 试验提前终止,检验效能不足以就死亡率得出结论。
  • 90天死亡率差异的调整分析P=.054,未达到统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although current guidelines suggest the use of regional citrate anticoagulation (which involves the addition of a citrate solution to the blood before the filter of the extracorporeal dialysis circuit) as first-line treatment for continuous kidney replacement therapy in critically ill patients, the evidence for this recommendation is based on few clinical trials and meta-analyses. OBJECTIVE: To determine the effect of regional citrate anticoagulation, compared with systemic heparin anticoagulation, on filter life span and mortality. DESIGN, SETTING, AND PARTICIPANTS: A parallel-group, randomized multicenter clinical trial in 26 centers across Germany was conducted between March 2016 and December 2018 (final date of follow-up, January 21, 2020). The trial was terminated early after 596 critically ill patients with severe acute kidney injury or clinical indications for initiation of kidney replacement therapy had been enrolled. INTERVENTIONS: Patients were randomized to receive either regional citrate anticoagulation (n = 300), which consisted of a target ionized calcium level of 1.0 to 1.40 mg/dL, or systemic heparin anticoagulation (n = 296), which consisted of a target activated partial thromboplastin time of 45 to 60 seconds, for continuous kidney replacement therapy. MAIN OUTCOMES AND MEASURES: Coprimary outcomes were filter life span and 90-day mortality. Secondary end points included bleeding complications and new infections. RESULTS: Among 638 patients randomized, 596 (93.4%) (mean age, 67.5 years; 183 [30.7%] women) completed the trial. In the regional citrate group vs systemic heparin group, median filter life span was 47 hours (interquartile range [IQR], 19-70 hours) vs 26 hours (IQR, 12-51 hours) (difference, 15 hours [95% CI, 11 to 20 hours]; P < .001). Ninety-day all-cause mortality occurred in 150 of 300 patients vs 156 of 296 patients (Kaplan-Meier estimator percentages, 51.2% vs 53.6%; unadjusted difference, -2.4% [95% CI, -10.5% to 5.8%]; unadjusted hazard ratio, 0.91 [95% CI, 0.72 to 1.13]; unadjusted P = .38; adjusted difference, -6.1% [95% CI, -12.6% to 0.4%]; primary adjusted hazard ratio, 0.79 [95% CI, 0.63 to 1.004]; primary adjusted P = .054). Of 38 prespecified secondary end points, 34 showed no significant difference. Compared with the systemic heparin group, the regional citrate group had significantly fewer bleeding complications (15/300 [5.1%] vs 49/296 [16.9%]; difference, -11.8% [95% CI, -16.8% to -6.8%]; P < .001) and significantly more new infections (204/300 [68.0%] vs 164/296 [55.4%]; difference, 12.6% [95% CI, 4.9% to 20.3%]; P = .002). CONCLUSIONS AND RELEVANCE: Among critically ill patients with acute kidney injury receiving continuous kidney replacement therapy, anticoagulation with regional citrate, compared with systemic heparin anticoagulation, resulted in significantly longer filter life span. The trial was terminated early and was therefore underpowered to reach conclusions about the effect of anticoagulation strategy on mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02669589.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Zarbock A, Küllmar M, Kindgen-Milles D, et al. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2020. PMID: 33095849. doi:10.1001/jama.2020.18618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。